- Source: Razpipadon
Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. It is taken via oral administration.
Razpipadon acts as a selective partial agonist of the dopamine D1 and D5 receptors. The drug has been found to increase willingness to exert effort for rewards in humans and hence appears to show pro-motivational effects.
The drug was originated by Pfizer and is under development by Cerevel Therapeutics. As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy.
See also
6-Br-APB
Mevidalen (LY-3154207)
Tavapadon (CVL-751)
References
External links
CVL-871 - AdisInsight
CVL-871 - Cerevel Therapeutics
